Data. حسب Chao Zhang (51048)

الموضوعات:

Molecular docking showed that ABT-199 can fit into active site of ALK^Mutant. حسب Richard Junior Zapata Dongo (17912565)

ALK^wt–ABT199 interactions. حسب Richard Junior Zapata Dongo (17912565)

Supplementary file 1_“We find that…” changing patterns of epistemic positioning in research writing.docx حسب Yanfang Yang (408813)

"…</p>Results<p>Our findings show that epistemic positioning has significantly decreased across all four disciplines over time, with writers increasingly preferring less use of epistemic markers in pursuit of an objective, data-based, and scientific style.…"

Data Sheet 2_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf حسب Mi-Ae Lyu (20413646)

"…UCB-Treg and ruxolitinib combination also downregulates the soluble form of inflammatory cytokines including IFN-γ, IP-10, TNF-α, IL-6, sCD40L, IL-17A, IL-17F, IL-1α, and LIF in cocultures. The addition of ruxolitinib increases UCB-Treg cell persistence in peripheral blood in vivo and decreases the soluble form of human inflammatory cytokines including IFN-γ, TNF-α, and sCD40L in plasma along with improvement of skin lesions in SLE xenografts. …"

Data Sheet 3_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf حسب Mi-Ae Lyu (20413646)

"…UCB-Treg and ruxolitinib combination also downregulates the soluble form of inflammatory cytokines including IFN-γ, IP-10, TNF-α, IL-6, sCD40L, IL-17A, IL-17F, IL-1α, and LIF in cocultures. The addition of ruxolitinib increases UCB-Treg cell persistence in peripheral blood in vivo and decreases the soluble form of human inflammatory cytokines including IFN-γ, TNF-α, and sCD40L in plasma along with improvement of skin lesions in SLE xenografts. …"

Data Sheet 1_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf حسب Mi-Ae Lyu (20413646)

"…UCB-Treg and ruxolitinib combination also downregulates the soluble form of inflammatory cytokines including IFN-γ, IP-10, TNF-α, IL-6, sCD40L, IL-17A, IL-17F, IL-1α, and LIF in cocultures. The addition of ruxolitinib increases UCB-Treg cell persistence in peripheral blood in vivo and decreases the soluble form of human inflammatory cytokines including IFN-γ, TNF-α, and sCD40L in plasma along with improvement of skin lesions in SLE xenografts. …"

Data Sheet 1_Dihydroartemisinin decreases pre-existing neutralizing antibodies against adeno-associated virus in challenged mice.pdf حسب Jingjing Fang (124938)

Changes in growth characteristics (A = shoot fresh weight; B = shoot dry weight; C = root fresh weight; D = root dry weight) of M. stenopetala under drought conditions.... حسب Nadia Khater (22553166)

الموضوعات:

Percent viability and cytotoxicity of NHBE cells are significantly altered by PAA exposure. حسب Ellie S. Burns (21246537)

"…(B) Cytotoxicity was assessed through production of lactase dehydrogenase (LDH); percent response significantly increased with concentration. Hexavalent chromium (Cr(VI)) was employed as a positive control exposure to compare the impacts of varying PAA vapor concentrations to a known, highly cytotoxic substance. …"

Line graph showing the values of inflammatory cytokines at baseline and after treatment. حسب Káryta Suely Macêdo Martins (22404155)

الموضوعات:

Clinical and Demographic Characteristics of the Study Population. حسب Káryta Suely Macêdo Martins (22404155)

الموضوعات:

Baseline and post-treatment results of categorical electrocardiographic variables in each study group. حسب Káryta Suely Macêdo Martins (22404155)

الموضوعات:

Baseline and post-treatment results of quantitative electrocardiographic variables in each study group. حسب Káryta Suely Macêdo Martins (22404155)

الموضوعات:

CONSORT diagram illustrating patient flow during the study. حسب Káryta Suely Macêdo Martins (22404155)

الموضوعات:

Baseline and Post-Treatment Results of Echocardiographic Variables in Each Experimental Group. حسب Káryta Suely Macêdo Martins (22404155)

الموضوعات:

Baseline and Post-Treatment Serum Cytokine Levels in Each Investigational Group. حسب Káryta Suely Macêdo Martins (22404155)

الموضوعات:

Baseline and Post-Treatment Serum Levels of NT-proBNP in Each Investigational Group. حسب Káryta Suely Macêdo Martins (22404155)

الموضوعات:

Variables obtained from the SF-36 quality of life questionnaire in each experimental group. حسب Káryta Suely Macêdo Martins (22404155)

الموضوعات:

Line graph showing the values of myocardial perfusion defects in the study groups. p = ANOVA Mixed Models. حسب Káryta Suely Macêdo Martins (22404155)

الموضوعات: